Advances in ¹⁷⁷Lu-PSMA and ²²⁵Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer

• Auteurs principaux: Sui Wai Ling (Auteur), Erik de Blois (Auteur), Eline Hooijman (Auteur), Astrid van der Veldt (Auteur), Tessa Brabander (Auteur)
• Format: Livre
• Publié: MDPI AG, 2022-10-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival benefit of classic treatment options with chemotherapy and drugs targeting androgen signaling is limited. Therefore, beta and alpha radionuclide therapy (RNT) have emerged as novel treatment options for patients...